Additionally, neither study included more recent therapeutic advancements such as trastuzumab deruxtecan (T-DXd), which has shown efficacy in HER2-positive gastric cancer after trastuzumab resistance [54,55]. The gene discussed is ERBB2; the disease is gastric cancer.